Ultragenyx Q2 revenue rises 28% to record high, net loss narrows

Ultragenyx Pharmaceutical

04/08/2026 21:18

Overview
US biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company history
Net loss for Q2 narrowed yr/yr, with loss per share improving to $0.90 from $1.17
Company reaffirmed 2026 revenue guidance and expects profitability in 2027

Outlook
Ultragenyx reaffirms 2026 total revenue guidance of $730 mln to $760 mln
Company maintains 2026 Crysvita revenue outlook at $500 mln to $520 mln
Ultragenyx expects 2026 combined R&D and SG&A expenses to be flat to slightly down vs 2025

Result Drivers
CRYSVITA SALES AND ROYALTIES - Q2 Crysvita revenue reached $156 mln, with company citing expected seasonality in US/Canada and ordering patterns in Latin America
EVKEEZA DEMAND - Q2 Evkeeza revenue was $21 mln, driven by increased demand from new country launches and early access
DOJOLVI JAPAN LAUNCH - Dojolvi launched in Japan in Q2 after approval, contributing to $27 mln in revenue

Company press release: ID:nGNX9dDLrD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.90
 
Q2 Net Loss
 
$92 mln
 
Q2 Operating Expenses
 
$289 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $47.50, about 89.8% above its August 3 closing price of $25.02

Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength
Aug 4 - Harmony Biosciences Q2 WAKIX revenue beats on patient growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)